Structure Therapeutics Doses First Patients In Phase 2b ACCESS Clinical Study Evaluating Oral Small Molecule GLP-1 Receptor Agonist GSBR-1290 In Obesity
Structure Therapeutics Doses First Patients In Phase 2b ACCESS Clinical Study Evaluating Oral Small Molecule GLP-1 Receptor Agonist GSBR-1290 In Obesity
Structure Therapeutics在评估用于肥胖的口服小分子GLP-1受体激动剂GSBR-1290的20亿ACCESS临床研究中给首批患者用药。
Structure Therapeutics Doses First Patients In Phase 2b ACCESS Clinical Study Evaluating Oral Small Molecule GLP-1 Receptor Agonist GSBR-1290 In Obesity
Structure Therapeutics 在 20 期为首批患者剂量 ACCESS 临床研究评估肥胖症患者口服小分子 GLP-1 受体激动剂 GSBR-1290